Page 88 - 《中国药科大学学报》2026年第2期

214 学报 Journal of China Pharmaceutical University 2026, 57(2): 206 − 214 第 57 卷

内递送是安全的。同时，LL/ZnPc 和 LL 对 PANC-1 [4] Donohoe C, Senge MO, Arnaut LG, et al. Cell death in photo-
dynamic therapy: from oxidative stress to anti-tumor
细胞的增殖抑制没有显著差异，表明 LL/ZnPc 具有
immunity[J]. Biochim Biophys Acta Rev Cancer, 2019, 1872(2):
较低的暗毒性。在光照条件下，LL/ZnPc+Laser 188308.
和 LL-PTP/ZnPc+Laser 对 PANC-1 细胞的增殖抑 [5] Broekgaarden M, Weijer R, Krekorian M, et al. Inhibition of
hypoxia-inducible factor 1 with acriflavine sensitizes hypoxic
制作用呈浓度依赖性。同时，在相同浓度下，LL-
tumor cells to photodynamic therapy with zinc phthalocyanine-
PTP/ZnPc+Laser 的细胞杀伤效果优于游离 ZnPc+ encapsulating cationic liposomes[J]. Nano Res, 2016, 9(6):
Laser，LL-PTP/ZnPc+Laser 组 IC 为 0 0.02 μg/mL（见 1639-1662.
5
[6] Bausch D, Thomas S, Mino-Kenudson M, et al. Plectin-1 as a
表 1），低于 LL/ZnPc+Laser 和 ZnPc+Laser 组，表明
novel biomarker for pancreatic cancer[J]. Clin Cancer Res,
胰腺癌靶向纳米载体 LL-PTP 可以提高 ZnPc 光动 2011, 17(2): 302-309.
力治疗的疗效。 [7] Kelly KA, Bardeesy N, Anbazhagan R, et al. Targeted nanopar-
ticles for imaging incipient pancreatic ductal
Table 1 IC 50 values of each treatment group adenocarcinoma[J]. PLoS Med, 2008, 5(4): e85.
[8] Zhang YJ, Sun T, Jiang C. Biomacromolecules as carriers in
Group IC 50 /（μg/mL）
drug delivery and tissue engineering[J]. Acta Pharm Sin B,
LND 94.83 2018, 8(1): 34-50.
ZnPc 3.25×10 7 [9] Roguin LP, Chiarante N, García Vior MC, et al. Zinc(II) ph-
ZnPc+Laser 1.10 thalocyanines as photosensitizers for antitumor photodynamic
therapy[J]. Int J Biochem Cell Biol, 2019, 114: 105575.
LND-low molecular weight heparin (LL) 66.03
[10] Chelminiak-Dudkiewicz D, Rybczynski P, Smolarkiewicz-
LL/ZnPc 69.61 Wyczachowski A, et al. Photosensitizing potential of tailored
LL/ZnPc+Laser 0.04 magnetite hybrid nanoparticles functionalized with levan and
LL-PTP/ZnPc+Laser 0.02 zinc (II) phthalocyanine[J]. Appl Surf Sci, 2020, 524: 146602.
[11] Qi JP, Hu XW, Dong XC, et al. Towards more accurate

bioimaging of drug nanocarriers: turning aggregation-caused
4 结 论 quenching into a useful tool[J]. Adv Drug Deliv Rev, 2019, 143:
206-225.
本研究提出了一种纳米载体（LL-PTP），通过 [12] Qiao JN, Liu SH, Huang YF, et al. Glycolysis-non-canonical
靶向递送难溶性光敏剂 ZnPc 至胰腺癌细胞增强 glutamine dual-metabolism regulation nanodrug enhanced the
phototherapy effect for pancreatic ductal adenocarcinoma treat-
PDT，该纳米系统展现出卓越的肿瘤靶向摄取效 ment[J]. J Colloid Interface Sci, 2024, 665: 477-490.
率。同时，当 ZnPc 在肿瘤细胞中释放时，其具有 [13] Ganesh AN, Donders EN, Shoichet BK, et al. Colloidal aggre-
“从关闭到打开”信号切换的能力。这些特性可以 gation: from screening nuisance to formulation nuance[J]. Nano
Today, 2018, 19: 188-200.
提高抗肿瘤疗效，有助于减少对正常组织的副作 [14] Ghezzi M, Pescina S, Padula C, et al. Polymeric micelles in
用。更重要的是，体外实验证实 LL-PTP/ZnPc+ drug delivery: an insight of the techniques for their characteriza-
Laser 组对胰腺癌细胞生长有显著抑制作用。这种 tion and assessment in biorelevant conditions[J]. J Control Re-
lease, 2021, 332: 312-336.
纳米载体负载 ZnPc 克服了传统光敏剂 ZnPc 在肿 [15] Patil S, Sandberg A, Heckert E, et al. Protein adsorption and
瘤治疗中难溶性和光毒性问题，并为癌症更好的 cellular uptake of cerium oxide nanoparticles as a function of
Zeta potential[J]. Biomaterials, 2007, 28(31): 4600-4607.
PDT 效果提供了一种潜在的策略。
[16] Hestand NJ, Spano FC. Expanded theory of H- and J-molecular
aggregates: the effects of vibronic coupling and intermolecular
charge transfer[J]. Chem Rev, 2018, 118(15): 7069-7163.
References
[17] Qiu YF, Chen PL, Liu MH. Interfacial assembly of an achiral
[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, zinc phthalocyanine at the air/water interface: a surface pres-
2022[J]. CA A Cancer J Clin, 2022, 72(1): 7-33. sure dependent aggregation and supramolecular chirality[J].
[2] Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer[J]. Langmuir, 2008, 24(14): 7200-7207.
Lancet, 2020, 395(10242): 2008-2020. [18] Zhang SW, Wang YQ, Kong ZQ, et al. Pure photosensitizer-
[3] Li XS, Lovell JF, Yoon J, et al. Clinical development and po- driven nanoassembly with core-matched PEGylation for imag-
tential of photothermal and photodynamic therapies for ing-guided photodynamic therapy[J]. Acta Pharm Sin B, 2021,
cancer[J]. Nat Rev Clin Oncol, 2020, 17(11): 657-674. 11(11): 3636-3647.